Drug Trial Radar · NCT01587768
WEUKBRE5555: IMI PROTECT(Work Package 2): Liver Injury & Antibiotics
Last checked: Nov 19, 2026Latest source record: Dec 10, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1
Actual
Start
Nov 2011
Primary completion
Jul 2014
Study completion Jul 2014
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Apr 30, 2012
Design
- Study type
- Observational
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The studies described in this protocol are all performed within the framework of PROTECT (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium) Workpackage 2 (WP2) and Workgroup 1. The primary aim of these studies is to develop, test and disseminate methodological standards for the design, conduct and analysis of Pharmacoepidemiological (PE) studies applicable to different safety issues and using different data sources. To achieve this, results from PE studies on 5 key adverse events (AEs) performed in different databases will be evaluated. Therefore, emphasis will be on the methodological aspects of the studies in this protocol and not on the clinical consequences of the association under investigation. The standards to develop will contribute to decreasing the discrepancies in results from different studies in the future and increase the usefulness and reliability of these studies for benefit-risk assessment in the EU. We propose to assess the association between antibiotics use and idiopathic acute liver injury with different study designs (descriptive, cohort, nested case-control and case crossover) across different primary care databases and to compare the results between databases, across designs to evaluate the impact of design/database/population differences on the outcome of the studied association. Specific aims (in each database): 1. To describe characteristics, clinical features, and risk factors for acute liver injury in patients exposed and unexposed to antibiotics. 2. To estimate the overall risk of acute liver injury associated with antibiotics exposure (users and non-users) in each database 3. To estimate the risk of acute liver injury associated with various antibiotics classes 4. To estimate the risk of acute liver injury associated with specific individual antibiotics 5. To assess the effect of dose and duration of use for specific individual antibiotics. 6. To compare the results of a case-control study with the results of a retrospective cohort study and self-controlled case series study in the different databases The proposed studies will be collected in populations from the following databases: The General Practice Research Database \[GPRD\] (UK), Health Improvement Network \[THIN\] (UK), BIFAP \[Base de datos Informatizada para estudios Farmacoepidemiologicos en Atencion Primaria\] (Spain)- the Bavarian Claims Database (Germany), Mondriaan (Netherlands), and the National Databases of Denmark.
Conditions
- Infections, Bacterial
Interventions
Antibiotic prescription during the study period between January 1, 2004 and December 31, 2009Drug
Antibiotics will be analysed overall, by class (tetracyclines, penicillins and betalactamics, cephalosporins, macrolides, aminoglycosides, quinolones and other antibiotics (sulphonamides \& others combinations)) and individually. The antibiotics administered to patients include: cefuroxime axetil, cefuroxime sodium, ceftazidime sodium, amoxicillin, amoxicillin/ clavulanate, ampicillin, ampicillin/cloxacillin, flucloxacillin, ticarcillin, and ticarcillin/ clavulanate.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Idiopathic acute liver injuryTime frame: Up to six years following drug exposure
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.